MX2017013133A - Dieta que imita el ayuno (fmd) y fármacos que reducen la glucosa protegen a células normales y generan condiciones de sensibilización al cáncer en respuesta a condiciones estándares y de alto contenido en glucosa inducidas por rapamicina y dexametasona. - Google Patents
Dieta que imita el ayuno (fmd) y fármacos que reducen la glucosa protegen a células normales y generan condiciones de sensibilización al cáncer en respuesta a condiciones estándares y de alto contenido en glucosa inducidas por rapamicina y dexametasona.Info
- Publication number
- MX2017013133A MX2017013133A MX2017013133A MX2017013133A MX2017013133A MX 2017013133 A MX2017013133 A MX 2017013133A MX 2017013133 A MX2017013133 A MX 2017013133A MX 2017013133 A MX2017013133 A MX 2017013133A MX 2017013133 A MX2017013133 A MX 2017013133A
- Authority
- MX
- Mexico
- Prior art keywords
- conditions
- fmd
- rapamycin
- dexamethasone
- standard
- Prior art date
Links
- 235000021439 fasting mimicking diet Nutrition 0.000 title abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 2
- 239000008103 glucose Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 title 1
- 229960003957 dexamethasone Drugs 0.000 title 1
- 229940127208 glucose-lowering drug Drugs 0.000 title 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
- 230000001235 sensitizing effect Effects 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 229960002930 sirolimus Drugs 0.000 title 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 4
- 238000002512 chemotherapy Methods 0.000 abstract 3
- 206010070834 Sensitisation Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000003642 hunger Nutrition 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008313 sensitization Effects 0.000 abstract 1
- 230000037351 starvation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562148451P | 2015-04-16 | 2015-04-16 | |
| PCT/US2016/028055 WO2016168802A2 (en) | 2015-04-16 | 2016-04-18 | Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013133A true MX2017013133A (es) | 2018-09-07 |
Family
ID=57126369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013133A MX2017013133A (es) | 2015-04-16 | 2016-04-18 | Dieta que imita el ayuno (fmd) y fármacos que reducen la glucosa protegen a células normales y generan condiciones de sensibilización al cáncer en respuesta a condiciones estándares y de alto contenido en glucosa inducidas por rapamicina y dexametasona. |
Country Status (14)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3291693A4 (en) * | 2015-05-06 | 2019-04-03 | University of Southern California | FASTENIMITIER AND IMPROVING DIET FOR THE TREATMENT OF HYPERTENSION AND LIPID DISORDER |
| JP2019505592A (ja) | 2016-02-15 | 2019-02-28 | ユニバーシティ オブ サザン カリフォルニア | 糖尿病及び他の疾患を治療するための胚様再生を刺激するための薬剤の組み合わせ及び方法 |
| KR20180136551A (ko) | 2016-05-11 | 2018-12-24 | 유니버시티 오브 써던 캘리포니아 | 위장 자가면역/염증 질환을 위한 면역조절 치료로서의 단식 모방 식이(fmd) |
| WO2018102393A1 (en) * | 2016-11-30 | 2018-06-07 | Cure Cancer Worldwide Llc | System for chemotherapy delivery and method of the same |
| US11284640B2 (en) * | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
| MX2020009613A (es) | 2018-03-15 | 2021-02-26 | Univ Southern California | Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd). |
| EP3801069A4 (en) | 2018-06-01 | 2022-03-16 | Cornell University | COMBINATION THERAPY FOR A PI3K-ASSOCIATED DISEASE OR DISORDER |
| US12628858B2 (en) | 2019-03-21 | 2026-05-19 | Cornell University | Therapy for colorectal and small intestine cancers |
| EP3963599B1 (en) | 2019-04-30 | 2026-06-03 | University of Southern California | Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad) |
| IT201900009954A1 (it) * | 2019-06-24 | 2020-12-24 | Fondazione Irccs Istituto Naz Dei Tumori | Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie |
| JP2023529504A (ja) * | 2020-06-14 | 2023-07-10 | エル－ニュートラ・インコーポレイテッド | ファスティング状態を維持及び延長する断続的なファスティングバー／ドリンク |
| WO2022008943A1 (ru) * | 2020-07-10 | 2022-01-13 | Елена Анатольевна МАРТЫНОВА | Способ проведения курса голодания для тяжелобольных пациентов |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011050302A2 (en) * | 2009-10-22 | 2011-04-28 | University Of Southern California | Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
| AU2011339929B2 (en) * | 2010-12-06 | 2017-05-11 | Tom C. Tsang | Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer |
| CA2900782C (en) * | 2013-02-12 | 2022-09-27 | University Of Southern California | Methods and diets to protect against chemotoxicity and age related illnesses |
| RU2727960C2 (ru) * | 2013-07-01 | 2020-07-28 | Юниверсити Оф Саутерн Калифорния | Состояние воздержания от пищи в качестве диетического лечения диабета |
| CN106456631A (zh) * | 2014-03-06 | 2017-02-22 | 南加利福尼亚大学 | 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用 |
-
2016
- 2016-04-18 BR BR112017022244A patent/BR112017022244A2/pt not_active IP Right Cessation
- 2016-04-18 AU AU2016248443A patent/AU2016248443B2/en active Active
- 2016-04-18 CA CA3108664A patent/CA3108664A1/en not_active Abandoned
- 2016-04-18 CA CA2982875A patent/CA2982875C/en active Active
- 2016-04-18 MX MX2017013133A patent/MX2017013133A/es unknown
- 2016-04-18 KR KR1020177032463A patent/KR20180002677A/ko not_active Ceased
- 2016-04-18 HK HK18109338.2A patent/HK1249858A1/zh unknown
- 2016-04-18 EP EP23209796.4A patent/EP4299061A3/en active Pending
- 2016-04-18 CN CN201680022154.8A patent/CN107613979A/zh active Pending
- 2016-04-18 JP JP2017553410A patent/JP2018511625A/ja active Pending
- 2016-04-18 US US15/131,586 patent/US20160303056A1/en not_active Abandoned
- 2016-04-18 WO PCT/US2016/028055 patent/WO2016168802A2/en not_active Ceased
- 2016-04-18 EP EP16780985.4A patent/EP3283073A4/en not_active Ceased
- 2016-04-18 RU RU2017136423A patent/RU2734774C2/ru active
-
2017
- 2017-10-15 IL IL255026A patent/IL255026A0/en unknown
- 2017-11-14 ZA ZA2017/07710A patent/ZA201707710B/en unknown
-
2020
- 2020-10-02 JP JP2020168000A patent/JP2021008491A/ja active Pending
-
2021
- 2021-01-12 US US17/147,280 patent/US20210137856A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017136423A3 (cg-RX-API-DMAC10.html) | 2019-09-04 |
| CN107613979A (zh) | 2018-01-19 |
| EP4299061A2 (en) | 2024-01-03 |
| US20210137856A1 (en) | 2021-05-13 |
| RU2734774C2 (ru) | 2020-10-23 |
| EP4299061A3 (en) | 2024-02-28 |
| AU2016248443B2 (en) | 2021-03-18 |
| JP2021008491A (ja) | 2021-01-28 |
| IL255026A0 (en) | 2017-12-31 |
| ZA201707710B (en) | 2019-04-24 |
| EP3283073A2 (en) | 2018-02-21 |
| BR112017022244A2 (pt) | 2018-07-10 |
| JP2018511625A (ja) | 2018-04-26 |
| HK1249858A1 (zh) | 2018-11-16 |
| KR20180002677A (ko) | 2018-01-08 |
| CA2982875A1 (en) | 2016-10-20 |
| AU2016248443A1 (en) | 2017-11-02 |
| EP3283073A4 (en) | 2019-02-13 |
| WO2016168802A2 (en) | 2016-10-20 |
| CA3108664A1 (en) | 2016-10-20 |
| CA2982875C (en) | 2021-10-19 |
| RU2017136423A (ru) | 2019-05-16 |
| US20160303056A1 (en) | 2016-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4299061A3 (en) | Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone | |
| Kale et al. | Targeting ion channels for cancer therapy by repurposing the approved drugs | |
| Nagrial et al. | Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials | |
| MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| PH12019502316A1 (en) | Combination cancer immunotheraphy with pentaaza macrocyclic ring complex | |
| BR112018002941A2 (pt) | métodos para tratar câncer pancreático metastático usando terapias de combinação compreendendo irinotecano lipossomal e oxaliplatina | |
| Hill et al. | How cancer therapeutics cause accelerated aging: Insights from the hallmarks of aging | |
| BR112018004207A2 (pt) | biomarcadores e métodos de tratamento de câncer | |
| JP2018511625A5 (cg-RX-API-DMAC10.html) | ||
| BR112018007139A2 (pt) | ?método de proteção contra lesão de isquemia-reperfusão, e, método para tratar ou proteger um sujeito de afinamento ou perda da cfnr e lesão de isquemia-reperfusão associada a tratamento ivav? | |
| BR112016016932A2 (pt) | Tratamento de neoplasia | |
| MX2016016667A (es) | Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer. | |
| BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose | |
| BR112017004292A2 (pt) | unidade de infusão, para a preparação sequencial de uma bebida, bem como dispositivo e processo para preparaçáo de uma bebida de pelo menos duas cápsulas | |
| NZ734252A (en) | Blockers of the growth hormone receptor in disease prevention and treatment | |
| Sivolap et al. | Wernicke encephalopathy and Korsakoff's psychosis: clinical-pathophysiological correlation, diagnostics and treatment | |
| IL283422A (en) | Methods of treating or preventing asthma by adding an IL-4R antagonist | |
| Jiang | Fotemustine/oxaliplatin | |
| UA99731U (ru) | Способ лечения мукополисахаридозов у больных разных возрастных групп | |
| Manmuan | EFFECTS OF SALINOMYCIN ON CELL VIABILITY, MIGRATION, INVASION AND INCREASING TAMOXIFEN SENSITIVITY IN ANTI-ESTROGEN RESISTANT BREAST CANCER CELLS | |
| UA90868U (uk) | Спосіб профілактики контраст-індукованої нефропатії | |
| Fujita | Mechanisms of resistance to molecular targeted drugs | |
| UA111014C2 (uk) | Спосіб лікування генералізованих тривожних розладів онкологічних хворих, які перенесли хірургічне втручання з формуванням кишкової стоми | |
| Arruti | Cyanocobalamin/dexamethasone/lidocaine/thiamine | |
| UA94513U (uk) | Спосіб лікування дисменореї в дівчат-підлітків |